Tsurutani Junji

ツルタニジュンジ | Tsurutani Junji

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (14)： Clinical Oncology, Medical Oncology,Breast Cancer, Clinical Trial, Drug Development, Molecular Target Medicine,Antibody Drug Conjugate, Cell Signaling , バイオマーカー , 細胞内トラフィッキング , 細胞内シグナル , 薬剤耐性 , 分子標的薬 , 抗体薬物複合体 , HER2 , Translational research , Lung Cancer , Breast Cancer , Cancer , Clinical Trial , Medical Oncology

Research theme for competitive and other funds (13)：

2022 - 2025 To investigate mechanisms and a role of folate receptor induction in tumor development
2023 - 2024 アベマシクリブを服用した転移性乳癌患者を対象に使用実態及び有効性を評価する国際共同観察研究(ABCR2)
2020 - 2023 CDK4/6阻害剤気治療後の腫瘍組織を用いてFoundation one検査を施行した症例/FGFR mutation/amlificationを認めた症例を対象としたRNA-seqによる網羅的遺伝子解析と、EMT-score/IO subtype同定による、ホルモン療法耐性、化学療法効果の予測性の検証試験
2019 - 2022 Establishment of hand therapy technique to improve numbness symptoms after chemotherapy for breast cancer patients
2020 - 2021 Abemaciclib for metastatic breast cancer (MBC) Chart Review

Show all

Papers (222)：

H. Sakai, J. Tsurutani, Y. Ozaki, H. Ishiguro, K. Nozawa, T. Yamanaka, K. Aogi, K. Matsumoto, T. Iwasa, M. Tokiwa, et al. A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). Annals of Oncology. 2024
Takahiro Nakayama, Naoki Niikura, Takashi Yamanaka, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Hironori Nomura, Shosuke Kita, Miki Yamaguchi, et al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM). Breast cancer (Tokyo, Japan). 2024
佐治重衡, 山下年成, 高野利実, 内藤陽一, 常泉道子, 吉村章代, 高橋將人, 鶴谷純司, 岩谷胤生, 北田正博, et al. HER2陽性進行・再発乳癌に対するHP療法にタキサン併用とエリブリン併用を比較する第III相JBCRG-M06試験. 日本乳癌学会総会プログラム抄録集. 2024. 32回. 66-66
Toshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, Naoki Niikura, Yeon Hee Park, Keun Seok Lee, Yee Soo Chae, Binghe Xu, Xiaojia Wang, Seock-Ah Im, et al. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast cancer (Tokyo, Japan). 2024. 31. 5. 858-868
Naoki Miyazaki, Toshiki Iwasaki, Hitomi Sakai, Rurina Watanuki, Yoshinori Tanizawa, Zhihong Cai, Tsutomu Kawaguchi, Junji Tsurutani, Kengo Nagashima. Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Current medical research and opinion. 2024. 40. 5. 1-11

ｍore...

MISC (339)：

鶴谷純司. 【教育】文部科学省がん専門医療人材養成事業 8大学関東がんプロのeラーニング作成. 2024
講師:厚生労働省医政局研究開発政策課治験推進室片岡智子. 【教育】先端がん治療研究セミナー(文科省がんプロ共催、昭和大学学士会後援) 演題:臨床研究法を取り巻く環境と展望. 2023
治療前CD163はニボルマブ+化学療法における予後不良因子(WJOG9917BTR). 日本癌治療学会学術集会抄録集. 2023. 61回. O25-3
ファシリテーター:鶴谷純司. 【教育】文部科学省がん専門医療人材養成事業 4大学連携多職種ワークショップ. 2023
尾崎由記範, 鶴谷純司, 向原徹, 岩朝勤, 高橋將人, 田辺裕子, 川端英孝, 増田慎三, 二村学, 南博信, et al. HER2陰性転移再発乳癌に対するニボルマブ+ベバシズマブ+パクリタキセル併用療法の第II相試験(WJOG9917B). 日本乳癌学会総会プログラム抄録集. 2023. 31回. 65-65

ｍore...

Books (14)：

新臨床腫瘍学(改訂第7版)
南江堂 2024
図解ですっきり!抗がん薬の薬理作用
南江堂 2023
乳癌診療 stage of the art 科学に基づく最新診療
医歯薬出版株式会社 2022
遺族ケアガイドライン 2022年版
金原出版 2022
乳腺腫瘍学(第4版)
金原出版株式会社 2022

ｍore...

Lectures and oral presentations (202)：

Post-T-DXd treatment in patients with HER2-positive metastatic breast cancer: A multicenter cohort study (EN-SEMBLE)
(JSMO 2024)
Toxicity of combination therapy with nivolumab and abemaciclib in HR-positive metastatic breast cancer: WJOG11418B
(JSMO 2024)
Dato-DXd vs chemotherapy for patients with inoperable/metastatic HR+/HER2- breast cancer: TROPION-Breast01 Asian subset
(JSMO 2024)
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases:an updated overall survival analysis using data froma multicenter retrospective study(ROSET-BM study)
(SABCS 2023)
Real-world experience with trastuzumab deruxtecan in patients with breast cancer: 6 month-interim analysis of an all-patient postmarketing surveillance in Japan
(SABCS 2023)

ｍore...

Professional career (1)：

医学博士 (長崎大学医学部大学院)

Work history (8)：

2018/08 - 現在 Showa University Advvanced Cancer Translational Research Institute Head, professor
2021/02 - Showa University Hospital The Innovative Center of Translational Research and Clinical Science for Cancer Therapy Professor
2008/01 - 2018/07 Kindai University Faculty of Medicine Department of Medical Oncology Assosiate professor
2006/08 - 2007/12 北九州市立八幡病院医長
2001/04 - 2007/03 Nagasaki University,Graduate School of Medicine control of infection diseases unit Graduate student

Show all

Committee career (12)：

2024/02 - 現在 Japanese Society of Medical Oncology Membership committee
2011/04 - 現在一般社団法人日本乳癌学会評議員
2011/04 - 現在公益社団法人日本臨床腫瘍学会協議員
2024/02 - JSMO director
2023/10 - Monarh study translational research, steering committee

Show all

Awards (8)：

2021/06 - Showa University Kamijo Memorial Best Publication Award Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
2020/10 - JBCS Best of Breast Cancer Award
2020/10 - Japan Breast Cancer Society Best of Breast Cancer Award Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study
2016/04 - Japanese Society of Clinical Oncology Research Award cfDNA analysis in HER2 positve breast cancer
2015/10 - Kindai Univ. Medical Association Research Award Phase I study of nab-paclitaxel and S-1 in ABC

Show all

Association Membership(s) (10)：

日本癌治療学会 , 日本乳癌学会 , 日本臨床腫瘍学会 , Japanese Cancer Association , American Society of Clinical Oncology , American Association of Cancer Research , 日本内科学会 , 日本呼吸器学会 , 日本肺癌学会 , 日本気管支鏡学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page